Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an…

• Q
  QIAGEN
• P
  Pfizer
• A
  AstraZeneca
• M
  Merck
• AS
  American Society of Transplantation
• GS
  Gilead Sciences
• RP
  Regeneron Pharmaceuticals
• HF
  HHV-6 Foundation
• FP
  FORUM Pharmaceuticals
• M
  Moderna
• UC
  University College London
• AP
  Astellas Pharma
• TM
  Takeda Medical Research Foundation
• SP
  SymBio Pharmaceuticals Limited
• A
  AiCuris
• UF
  U.S. Food and Drug Administration
• G
  Genentech